Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia

Clinical Infectious Diseases

Volumn 36, Issue 10, 2003, Pages 1229-1231

  Odds, Frank C ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

BLOOD CULTURE; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DRUG MIXTURE; HUMAN; INTERMETHOD COMPARISON; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; DRUG THERAPY, COMBINATION; FLUCONAZOLE; FUNGEMIA; HUMANS;

EID: 0038183844     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374856     Document Type: Review

References (21)

1. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301:126-31.
2. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy of candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221-8 (in this issue).
3. Edwards JE, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25:43-59.
4. Andes D, van Ogtrop H. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999; 43:2116-20.
5. Kibbler CC. Fungaemia and disseminated fungal infection. In: Kibbler CC, Mackenzie DWR, Odds FC, eds. Principles and practice of clinical mycology. Chichester, UK: Wiley, 1996:143-64.
6. Chryssanthou E, Klingspor L, Tollemar J, et al. PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients. Mycoses 1999; 42:239-47.
7. Lewis RE, Lund BC, Klepser ME, et al. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother 1998; 42:1382-6.
8. Vazquez JA, Arganoza MT, Vaishampayan JK, et al. In vitro interaction between amphotericin B and azoles in Candida albicans. Anti-microb Agents Chemother 1996; 40:2511-6.
9. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985; 151:902-10.
10. Schaffner A, Bohler A. Amphotericin-B refractory aspergillosis after itraconazole - evidence for significant antagonism. Mycoses 1993; 36:421-4.
11. Polak A, Scholer HI, Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy 1982; 28:461-79.
12. Polak A. Combination therapy of experimental candidosis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 1987; 33:381-95.
13. Van Cutsem J. Therapy of experimental meningeal and disseminated cryptococcosis. Mycoses 1993; 36:357-67.
14. George D, Kordick D, Miniter P, et al. Combination therapy in experimental invasive aspergillosis. J Infect Dis 1993; 168:692-8.
15. Polak A. The past, present and future of antimycotic combination therapy. Mycoses 1999; 42:355-70.
16. Lewis RE, Klepser ME, Pfaller MA. Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis. J Infect Dis Pharmacother 1998; 3:61-84.
17. Kamberi P, Atsuro H, Takayoshi T, et al. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice. Chemotherapy 1998; 44:55-62.
18. Sugar AM, Hitchcock CA, Troke PF, et al. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995; 39:598-601.
19. Louie A, Kaw P, Banerjee P, et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother 2001; 45:485-94.
20. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Anti-microb Agents Chemother 1995; 39:1907-12.
21. Sugar AM. Antifungal combination therapy: where we stand. Drug Res Updates 1998; 1:89-92.